Chinese company started a clinical trial of CAR-T Cell in the treatment of adult relapsed refractory acute Lymphoblastic Leukemia

Photo by Maria Ionova

Hebei Senlang Biotechnology Inc., Ltd is recruiting patients for the clinical trial of Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation.

This is phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic leukemia bridging allogeneic hematopoietic stem cell transplantation.

This trial openly recruited 50 patients into the group and were given CAR-T treatment. Patients participating in clinical trials will be tested and evaluated in terms of treatment safety, efficacy, and response duration. As assessed by clinicians, adult B-ALL patients who meet the enrollment criteria, after adequate communication, the patient or family members voluntarily join the clinical study, and are willing to bridge allogeneic hematopoiesis within 3 months after enrollment using CAR-T therapy.

Among primary outcome measures are the number of participants with severe/adverse events as a measure of safety.

The study will take place at the No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04626726.